SCHEMBL630198

SCHEMBL630198

CNc1ncc(Br)c(C(=O)OC)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
CHEK1 O14757 1/20 0.36
NTRK2 Q16620 1/20 0.36
MAPK1 P28482 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
LRRK2 Q5S007 2/20 0.33
JAK2 O60674 1/20 0.33
ULK1 O75385 1/20 0.33
PRKAA2 P54646 1/20 0.33
PRKAA1 Q13131 1/20 0.33
ULK2 Q8IYT8 1/20 0.33
F2 P00734 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MERTK Q12866 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651377 0.80 NPSR1 (0.44) NPSR1MAPK1LRRK2JAK2MAPT
SCHEMBL31500546 0.79 NPSR1 (0.47) NPSR1MAPK1L3MBTL1SMN1; SMN2MAPT
SCHEMBL7452572 0.79 NPSR1 (0.47) NPSR1MAPK1L3MBTL1SMN1; SMN2MAPT
SCHEMBL38663560 0.78 NPSR1 (0.45) NPSR1CHEK1NTRK2MAPK1L3MBTL1
SCHEMBL22389946 0.78 NPSR1 (0.45) NPSR1MAPK1L3MBTL1SMN1; SMN2KMT2A
SCHEMBL2159167 0.75 NPSR1 (0.42) NPSR1MAPK1L3MBTL1SMN1; SMN2GAA
SCHEMBL29439591 0.75 KMT2A (0.47) NPSR1L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL628538 0.75 KMT2A (0.47) NPSR1L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL2159888 0.75 NPSR1 (0.42) NPSR1MAPK1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL2160050 0.74 NPSR1 (0.41) NPSR1MAPK1L3MBTL1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
US-9062043-B2 Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES, INC. (TW) 2015-06-23 US disclosed
EP-2061765-B1 Serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES INC (TW) 2014-10-22 EP disclosed
EP-2061765-B1 Serine-threonine protein kinase and PARP modulators SENHWA BIOSCIENCES INC (TW) 2014-10-22 EP disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
CN-102481289-A Method of treating disorders associated with protein kinase ck2 activity CYLENE PHARMACEUTICALS INC 2012-05-30 CN disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
CN-101528704-A Serine-threonine protein kinase and PARP modulators CYLENE PHARMACEUTICALS INC (US) 2009-09-09 CN disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 NPSR1 3994/4885CHEK1 685/4885NTRK2 1310/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 NPSR1 3655/4885CHEK1 16/4885NTRK2 2327/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 NPSR1 3994/4885CHEK1 685/4885NTRK2 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.